Interpretive Criteria for Disk Diffusion Susceptibility Testing of Ulifloxacin, the Active Metabolite of Prulifloxacin

Authors: Montanari, M.P.; Ferrante, L.; Tili, E.; Cochetti, I.; Rossi, V.; Varaldo, P.E.

Source: Journal of Chemotherapy, Number 2, April 2005 , pp. 138-142(5)

Buy & download fulltext article:

Price: $48.00 plus tax (Refund Policy)

Abstract:

Prulifloxacin, a new fluoroquinolone, is a prodrug whose active compound, ulifloxacin, is derived from its transformation after oral administration and intestinal absorption. Based on early pharmacokinetic and pharmacodynamic data, the following MIC breakpoints have tentatively been proposed: ≤1 μg/ml, susceptible; 2 μg/ml, intermediate; and ≥4 μg/ml, resistant. In this report, ulifloxacin MIC vs. zone diameter scattergrams and discrepancy rates were analyzed in 461 freshly isolated clinical strains (237 Enterobacteriaceae, 101 nonfermenters, and 123 Grampositive bacteria). In agreement with the guidelines of the National Committee for Clinical Laboratory Standards, a modification of the error rate-bounded method was used to select disk diffusion test breakpoints. The following zone diameter breakpoints were chosen and are proposed herein for the interpretation of ulifloxacin disk (5 μg) test results: ≤15 and ≥19 mm for Enterobacteriaceae, ≤16 and ≥20 mm for nonfermenters, and ≤14 and ≥18 mm for Gram-positive bacteria. By applying these breakpoint values, no very major errors were detected, while major and minor errors were largely below the accepted discrepancy rates.

Keywords: quinolone antibiotics; fluoroquinolones; error rate-bounded method; ulifloxacin; discrepancy rates; disk diffusion susceptibility testing; Prulifloxacin; interpretive criteria; Break points

Document Type: Research Article

Publication date: 2005-04-01

More about this publication?